A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382
← catalyst calendarSponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 2
Status
Terminated
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
163actual
Sites
80
Countries
Belgium, Brazil, Canada +10
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Company Decision
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-10-12 | actual | When the study began enrolling |
| Primary completion | 2025-09-22 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-09-22 | actual | The whole study's end, after follow-up |
| First posted | 2023-09-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Human Immuno-deficiency Virus (HIV) Disease
Interventions
- Drug: Budigalimab — also filed as ABBV-181
- Drug: Placebo for Budigalimab
- Drug: ABBV-382
- Drug: Placebo for ABBV-382
- Drug: Budigalimab — also filed as ABBV-181
Primary outcomes
what the primary-completion date above is the date OFPercentage of Participants with Viral Control Without Antiretroviral Therapy (ART) Restart
measured Week 24
Number of Participants with Adverse Events (AEs)
measured Up to approximately Week 112
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed